Botanix Pharmaceuticals Limited (AU:BOT) has released an update.
Botanix Pharmaceuticals Limited, a clinical dermatology company, is set to host a webinar to discuss its market strategy and upcoming commercial launch of SofdraÔ, the first FDA-approved new chemical entity for treating primary axillary hyperhidrosis. The event will feature Botanix executives and notable guests from the International Hyperhidrosis Society, UpScript Health, and Klick Health. The webinar aims to offer insights into the treatment of this challenging medical condition and Botanix’s role in providing novel solutions.
For further insights into AU:BOT stock, check out TipRanks’ Stock Analysis page.
